Glycolysis inhibitors for anticancer therapy: A review of recent patents

Recent Patents on Anti-Cancer Drug Discovery

Volumn 11, Issue 3, 2016, Pages 297-308

  Sheng, Huaming ^a   Tang, Weijuan ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Cancer; Glycolysis; Glycolytic enzymes; Inhibitors; Metabolic pathway; Warburg effect

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ANTINEOPLASTIC AGENT; GLUCOSE TRANSPORTER; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOLYSIS INHIBITOR; HEXOKINASE; LACTATE DEHYDROGENASE; LONIDAMINE; MONOCARBOXYLATE TRANSPORTER; PHOSPHOGLYCERATE MUTASE; PROTEIN HISTIDINE KINASE; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE KINASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE;

ARTICLE; CANCER THERAPY; CELL GROWTH; CELL PROLIFERATION; CHEMICAL STRUCTURE; ENZYME INDUCTION; GLUCOSE TRANSPORT; HUMAN; OXIDATIVE PHOSPHORYLATION; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GLYCOLYSIS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLYCOLYSIS; HEXOKINASE; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATENTS AS TOPIC; PHOSPHOFRUCTOKINASES; PROTEIN-SERINE-THREONINE KINASES; PYRUVATE KINASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84983798027     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1574892811666160415160104     Document Type: Article

References (106)

1. Heiden VMG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009; 324 (5930): 1029-33.
2. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4 (11): 891-9.
3. Galluzzi L, Kepp O, Vander Heiden M, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013; 12(11): 829-46.
4. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and Beyond. Cell 2008; 134 (5): 703-7.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-74.
6. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4: e532.
7. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124 (3215): 269-70.
8. Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66 (18): 8927-30.
9. Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerget Biomembranes 2007; 39 (3): 267-74.
10. Gatenby RA, Gillies RJ. Glycolysis in cancer: A potential target for therapy. Int J Biochem Cell Biol 2007; 39 (7-8): 1358-66.
11. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 2008; 13 (6): 472-82.
12. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabol 2008; 7 (1): 11-20.
13. Mathupala SP. Metabolic targeting of malignant tumors: Smallmolecule inhibitors of bioenergetic flux. Recent Pat Anticancer Drug Discov 2011; 6(1): 6-14.
14. Sheng H, Niu B, Sun H. Metabolic targeting of cancers: From molecular mechanisms to therapeutic strategies. Curr Med Chem 2009; 16(13): 1561-87.
15. Sheng H, Sun H. Synthesis, biology and clinical significance of pentacyclic triterpenes: A multi-target approach to prevention and treatment of metabolic and vascular diseases. Nat Prod Rep 2011, 28(3), 543-93.
16. Sheng H, Xiang Z, Ye J, Zheng J, Sun, H. Synthesis of novel alkylamino substituted cis-and trans-apovincamate derivatives. Chin J Nat Med 2010; 9(1): 51-7.
17. Zhang P, Hao J, Liu J, Lu Q, Sheng H, Zhang L, et al. Synthesis and biological evaluation of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod 2009; 72(8): 1414-8.
18. Butler MS. Natural products to drugs: Natural product-derived compounds in clinical trials. Nat Prod Rep 2008; 25(3): 475-516.
19. Kumar H, Kim IS, More SV, Kim BW, Choi DK. Natural productderived pharmacological modulators of Nrf2/ARE pathway for chronic diseases. Nat Prod Rep 2014; 31(1): 109-39.
20. Dobbelstein M, Moll U. Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 2014; 13(3): 179-96.
21. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202(3): 654-62.
22. Medina RA, Owen GI. Glucose transporters: Expression, regulation and cancer. Biol Res 2002; 35(1): 9-26.
23. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. J Nutr 2003; 89(1): 3-5.
24. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemotherapy Pharmacol 2007; 59(4): 495-505.
25. McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST, Shanmugam M. Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: Implications for glucose transporter-directed therapy. Blood 2012; 119(20): 4686-97.
26. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Therapeutics 2012; 11(8): 1672-82.
27. Chen, X., Bergmeier, S. Compositions and methods for glucose transport inhibition. WO2011119866 (2011).
28. Iring, H., Thomas, M., Stefan, G., Joachim, T., Hartmut, R., Holger, S., Bernd, B., Ludwig, Z., Knut, E., Marcus, K., Niels, L., Mélanie, H., Roland, N. Preparation of nitrogen-containing bicyclic heterocycles as inhibitors of glucose transport for treating proliferative, immune, or inflammatory disorders. WO2013182612 (2013).
29. Senn, S., Rachman, I. Cancer therapeutics comprising a micelle construct attached to a glut-1 antibody and an inhibitor of NF-κB. WO2013138735 (2013).
30. John, I., Patrick, S., Denise, C., Sandram T., Amato, G., Edwin, L., Olga, R., Michael, P.H., Muriel, B., Connie, S., Ray, T. Glucose transporter-1 (GLUT1) inhibitors for treatment of cancer. WO2012100223 (2012).
31. Kim, E., Cole, B., Sweetnam, P., Wong, E. Preparation of quinazoline derivatives as metabolic inhibitors. WO2012040499 (2012).
32. Iring, H., Thomas, M., Holger, S., Bernd, B., Arwed, C., Judith, G., Marcus, K., Mélanie, H., Roland, N., Heike, P., Maria, Q. NPyrazolyl quinolinecarboxamides as glucose transport inhibitors and their preparation. WO2015091428 (2015).
33. Iring, H., Thomas, M., Bernd, B., Ludwig, Z., Mélanie, H., Roland, N. Preparation of purinone derivatives as glucose transport inhibitors. WO2015078799 (2015).
34. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene, 2006; 25(34); 4683-96.
35. El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C. Sugar-free approaches to cancer cell killing. Oncogene 2010; 30(3): 253-64.
36. 2 and NO stresses. Biochem J 2002; 364: 349-59.
37. Robey RB, Hong R, Zhong L, Feng L, Zhang H. Effects of the antitumor agent 3-bromopyruvate (3BrPA) on glycolytic energy metabolism. FASEB J 2007; 21(6): A1190.
38. Ricci, J. Glycolytic inhibitor with cytotoxic agent for use in the treatment of a cancer. WO2012123774 (2012).
39. Ko, Y.H. Compositions comprising a cellular energy inhibitor and optionally a hexokinase inhibitor and methods for the treatment of cancer. WO2012018949 (2012).
40. Chen Z, Lu W, Garcia-Prieto C, Huang PJ. The Warburg effect and its cancer therapeutic implications. Bioenerg Biomembr 2007; 39(3): 267-74.
41. Brawer, M. K. Lonidamine: Basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol 2005; (Suppl 7): S21-6.
42. Lin, H., Luengo, J.I., Schulz, M., Xie, R., Zeng, J. Preparation of glucosamine derivatives as hexokinase inhibitors. WO2012083145 (2012).
43. Priebe, W., Conrad, C., Madden, T., Fokt, I., Szymanski, S., Antonovic, L. Fluorinated hexopyranose glycolysis inhibitors useful in the treatment of brain tumors. WO2009108926 (2009).
44. Harris, RA. Carbohydrate metabolism I: Major metabolic pathways and their control. 6th ed. John Wiley & Sons, Inc. Hoboken, NJ; 2006.
45. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003; 23(30): 7315-28.
46. Bando H, Atsumi T, Nishio T, Niwa H, Mishima S, Shimizu C, et al. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res 2005; 11(16); 5784-92.
47. Chesney J. 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis. Curr Opin Clin Nutr Metab Care 2006; 9(5): 535-39.
48. Chand, P., Tapolsky, G. H. Preparation of pyridynyl trifluoromethyl quinolinyl propenone derivatives for use as a PFKFB3 inhibitors. WO2013148228 (2013).
49. Lee, Y. H., Kim, J. D. Inhibitors of 6-phosphofructo-2-kinase/ fructose-2, 6-bisphosphatase 3 (PFKFB3) for cancer therapy. US20120302631 (2012).
50. Tapolsky, G., Chand, P., Trent, J. O., Telang, S., Clem, B. F., Chesney, J. A. Family of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3 (PFKFB3) inhibitors with anti-neoplastic activities. US20120177749 (2012).
51. Styrbjörn, B., Katarina, F., Charles, H., Evert, H., Mattias, J., Thomas, L., Jessica, M., Meral, S. Preparation of (hetero) aryl sulfonamides for treating inflammation and cancer. WO2012035171 (2012).
52. Johan, A., Evert, H., Thomas, L., Jessica, M., Meral, S., Mattias, J., Katarina, F., Kenth, H. Preparation of bisarylsulfonamides as inhibitors of 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase PFKFB3 and PFKFB4 isoforms useful in the treatment of inflammation and cancer. WO2011161201 (2011).
53. Chand, P., Chesney, J.A., Clem, B.F., Tapolsky, G.H., Telang, S., Trent, J.O. Small molecule inhibitors of 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 and glycolytic flux and their methods of use as anti-cancer therapeutics. WO2011103557 (2011).
54. Chesney, J., Trent, J.O., Telang, S., Clem, B., Meier, J. Family of PFKFB3 inhibitors with anti-neoplastic activities. WO2008156783 (2008).
55. Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL, et al. Emerging metabolic targets in cancer therapy. Front Biosci 2011; 16: 1844-60.
56. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth Sci Signal 2009; 2(97): ra73.
57. Lu, Z., Yung, W.K.A. Biomarkers for cancer characterization and treatment. WO2013066944 (2013).
58. Lei, Q., Lv, L., Li, D., Zhao, D., Guan, K., Xiong, Y., Linrui, T., Liu, Y. Acetylation inhibitor of pyruvate kinase 2 and its application. CN102805860 (2012).
59. Hu, X., Chen, J. Application of vitamin K-like compound in preparation of pyruvate kinase inhibitor. CN102552228 (2012).
60. Hu, X. Application of alkannin in preparing PKM2-type pyruvate kinase inhibitor. CN102068421(2011).
61. Kung, C. Activators of pyruvate kinase M2 and methods of treating disease. WO2013056153 (2013).
62. Salituro, F.G., Saunders, J.O. Preparation of oxobenzoxazinearylsulfonamide derivatives for use as PKM2 activators. WO2012088314 (2012).
63. Boxer, M.B., Shen, M., Auld, D.S., Thomas, C.J., Walsh, M.J. Preparation of tetrahydroquinoline derivatives as activators of human pyruvate kinase. WO2011137089 (2011).
64. Jennings, S., Barbara, B. Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development. US20110218176 (2011).
65. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11(1): 37-51.
66. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008; 283(42): 28106-14.
67. Chai, D., Colon, M., Dodson, C., Duffy, K. J., Shaw AN. Preparation of substituted quinoline derivatives as lactate dehydrogenase A inhibitors. WO2012061557 (2012).
68. Dang, C. V., Le, Q. H. T., Dinavahi, R. Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase. WO2010002465 (2010).
69. Chen, J., Hitosugi, T., Kang, S. Phosphoglycerate mutase 1 inhibitors and methods of use. WO2013055913 (2013).
70. Lisanti, M. P., Sotgia, F. Monocarboxylate transporter (MCT) protein inhibitors for treatment of cancer and related prognostic and therapeutic methods. WO2013112881 (2013).
71. Ishiguro T, Ishiguro M, Ishiguro R, Iwai S. Cotreatment with dichloroacetate and omeprazole exhibits a synergistic antiproliferative effect on malignant tumors. Oncol Lett 2012; 3(3): 726-28.
72. Ishiguro T, Ishiguro R, Ishiguro M, Iwai S. Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: In vivo experiments and a case report. Hepatogastroenterology 2012; 59(116): 994-6.
73. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic targeting therapy for cancer. Br J Cancer 2008; 99(7): 989-94.
74. Villalba, M., Krzywjnska, E., Allende, V., Nerea, R., Jean-Francois, L., Zhao, Y. Methods and pharmaceutical compositions comprising an inhibitor of pyruvate dehydrogenase kinase-1 (PDK1) for the treatment of refractory haematological malignancies. WO2013174997 (2013).
75. Michelle, M., Almeida, G.D., Jonathan, B., Grimm, R.N., Maccoss E.R., Tony, S., Catherine, W., Kevin, W. Preparation of heterocyclic compounds containing a thienyl ring as inhibitors of Janus kinases and PDK1 for treating myeloproliferative disorders and cancer. WO2009155156 (2010).
76. Calderini, M., Wucherer-Plietker, M., Graedler, U., Esdar, C. (Aminopyridine) benzimidazole and-imidazopyridine derivatives as PDK1 inhibitors and their preparation and use in the treatment of and inflammatory diseases. WO2011006567 (2011).
77. Dorsch, D., Wucherer-Plietker, M., Mueller, T.J.J., Merkul, E. 3-([1, 2, 3] Triazol-4-yl) pyrrolo[2,3-b] pyridine derivatives as PDK1 inhibitors and their preparation and use in the treatment of tumors. WO2010127754 (2010).
78. Paliwal, S., Tsui, H.C, Doll, R.J., Li, A.J., May, X., Rainka, M.P. Preparation of thiazole-4-carboxamide derivatives as inhibitors of phosphoinositide dependent kinase 1 (PDK1) for treating cancer. WO2011137219 (2011).
79. Heinrich, T., Wucherer-Plietker, M., Buchstaller, H.P. Preparation of 7-azaindole derivatives as PDK1 inhibitors useful in the treatment of tumors. WO2012175168 (2012).
80. Buchstaller, H.P., Wucherer-Plietker, M., Heinrich, T. Heteroarylsubstituted pyrrolo [2, 3-b] pyridine derivatives as PDK1 inhibitors and their preparation and use in the treatment of tumors. WO2012072200 (2012).
81. Heinrich, T., Wucherer-Plietker, M., Buchstaller, H.P. 1HPyrrolo[ 2,3-b] pyridine derivatives as PDK1 inhibitors and their preparation and use in the treatment of tumors. WO 2012059172 (2012).
82. Dorsch, D., Wucherer-Plietker, M., Mueller, T.J.J., Merkul, E. 7-([1,2,3] Triazol-4-yl) pyrrolo[2,3-b] pyrazine derivatives as PDK1 inhibitors and their preparation and use in the treatment of tumors and AIDS. WO2012059171 (2012).
83. Buchstaller, H. Preparation of N1-(3, 3, 3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase. WO 2015090496 (2015).
84. Sunil, P., Hon-Chung, T., Xiaolei, G., Hyunjin, M.K., Mary, A.C., Thierry, O.F., Jose, S.D. Preparation of novel heteroarylcarboxamide derivatives as PDK-1 inhibitors. WO2012058176 (2012).
85. Tsui, H.C., Paliwal, S., Gao, X., Kim, H.M., Doll, R.J. Preparation of thiazolecarboxamide derivatives as PDK1 inhibitors. WO2012058174 (2012).
86. Hon-Chung, T., Sunil, P., Hyunjin, M.K., Angela, D.K., Mary, A.C., Sara, J. E., Brian, A.M., Thierry, O.F., Ronald, J.D., Matthew, P.R., Ang, L. N-Phenyl imidazolecarboxamides as inhibitors of 3-phosphoinositide-dependent protein kinase-1 (PDK-1) and their preparation and use for the treatment of cancer. WO2011149874 (2011).
87. Axten, J.M., Brady, G.Jr., Gallagher, T.F., Heerding, D.A., Medina, J.R., Romeril, S.P. 1,2-Dihydroindazolo[4,3-bc] [1,5] benzoxazepines and related derivatives as PDK1 inhibitors and their preparation and use for the treatment of cancer. WO2010120854 (2010).
88. Jeffrey, M.A., Charles, W.B., Gerald, P.B., Yanhoug, G.F., Seth, W.G., Jesus, R.M., William, H.M., Stuart, P.R. Preparation of 6-(4-pyrimidinyl)-1H-indazole derivatives as PDK1 inhibitors. WO2010059658 (2010).
89. Francis, L.A., Jeffrey, M.A., Maria, C.-K., Michael, L.M., Vipulkumar, K.P., Xinrong, T., Christopher, R.W., Allison, K.D. Pyrido[4,3-d] pyrimidin-5(6H)-one derivatives as PDK1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2010019637 (2010).
90. Arndt, J., Chan, T., Guckian, K., Kumaravel, G., Lee, W.C., Lin, E.Y.S. Preparation of heterocyclic compounds useful as PDK1 inhibitors. WO2011044157 (2011).
91. Kenneth, E.L., Kathy, C., Edward, Y.-S.L., Thinh, B.N., Bradley, T.T., Daniel, A.E., Kevin, G., Robert, L.S., Wen-Cherng, L., Lihong, S., Stig, H., Nuzhat, P., Lei, Z. Preparation of pyridinonyl PDK1 inhibitors. WO2008005457 (2008).
92. Engelhardt, H., Kofink, C., Mcconnell, D. Preparation of heterocyclic carboxylic acid amides as PDK1 inhibitors. WO2011131741 (2011).
93. Wissner, A., Venkatesan, A.M. Pyrimido [5,4-c] quinoline-2,4-diamine derivatives as PDK-1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2008109599 (2008).
94. Savithri, R., Xiaodong, L., Sharada, S., Alice, C.R., Xiaojing, M.W., Rama, J., Jeremy, M.M., Steven, E.B., Robert, L.W., Wei, S., Yasheen, Z., Jeffrey, D., Mina, A., Payman, A. Preparation of quinazolines for PDK1 inhibition. WO2008079988 (2008).
95. Chen, C.S., Chiu, H.C., Wang, D. Pyrazole derivatives as antiinfective agents against intracellular pathogens and PDK-1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer, bacterial and viral infections. US20090111799 (2009).
96. Ekaterina, K., Christopher, D., Tony, S., Jonathan, Y., Alan, N., Michael, A., Kevin, A.K., David, J.G., Joon, O.J., Rachel, N.M., Solomon, K. Preparation of benzonaphthyridinones as inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1. WO2008112217 (2008).
97. Sakai, N. Expression of 3-phosphoinositide-dependent protein kinase 1 (PDK-1) inhibitor in mammalian cells and uses in treating diseases related to phosphorylation of PDK-1. WO2005019451 (2005).
98. Lee, T., Lee, I., Liu, K., Kim, N., Lee, D., Yoo, E.K. Preparation of 3-aryl-1,2,4-triazole derivatives as pyruvate dehydrogenase kinase inhibitors. WO 2015167211 (2015).
99. Chuang, D.T., Tso, S., Qi, X., Gui, W., Wu, C.Y., Chuang, J.L. Inhibitors of mitochnondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof. WO2015089360 (2015).
100. Brough, P.A., Macias, A., Roughley, S.D., Wang, Y., Parsons, R. J., Northfield, C.J. Preparation of resorcinol N-aryl amide compounds, for use as pyruvate dehydrogenase kinase inhibitors. WO2015040425 (2015).
101. Brough, P.A., Macias, A., Roughley, S.D., Stokes, S., Davies, N.G.M. Preparation of tetrahydroisoquinoline compounds and their use as pyruvate dehydrogenase kinase inhibitors. WO2015040424 (2015).
102. Motomura, T., Matsuo, T., Shomi, G. Preparation of fluoreneamide compound as PDHK (pyruvate dehydrogenase kinase) inhibitor and pharmaceutical application therefor. WO2015002118 (2015).
103. Motomura, T., Matsuo, T., Shomi, G., Inoue, M. Pyrazole-alcohol compound as PDHK (pyruvate dehydrogenase kinase) inhibitor and pharmaceutical application therefor. WO2015002119 (2015).
104. Fantin, V.R., St-Pierre, J., Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9(6): 425-34.
105. Hitosugi T, Zhou L, Elf S, Fan J, Kang HB, Seo JH, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 2012; 22(5): 585-600.
106. Gao C, Wang C, Liu B, Wu H, Yang Q, Jin J. Intermittent hypoxia preconditioning-induced epileptic tolerance by upregulation of monocarboxylate transporter 4 expression in rat hippocampal astrocytes. Neurochem Res 2014; 39(11): 2160-9.